Clinical Trial Update: A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating dalteparin as an anticoagulation method in patients undergoing quotidian and nocturnal home hemodialysis, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Failure

Drugs mentioned

• Dalteparin (dalteparin)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Kidney Failure | Phase 4 | Status: COMPLETED